Zepbound

News

Judge backs Lilly in Novo lawsuit over weight-loss drug ads

A US judge has blocked Novo's request for an injunction on Eli Lilly's advertising for weight-loss and diabetes drugs Mounjaro and Zepbound.

News

Lilly's Zepbound enhances Taltz efficacy in psoriasis study

A study has shown that the efficacy of Lilly's psoriasis therapy Taltz is improved when it is given in combination with weight-loss drug Zepbound.

News

Lilly fleshes out triple G data in diabetes and obesity

Eli Lilly has revealed more data with its triple G agonist retatrutide, boosting its credentials as the next big thing in cardiometabolic diseases.

News

Lilly's GLP-1s race away in Q2, though Foundayo falls short

Eli Lilly has posted another record quarter of revenue growth, up 48% to $23bn, with Mounjaro and Zepbound now making up two-thirds of the total.

News

Novo sues Lilly over 'misleading' GLP-1 ad campaigning

The rivalry between Novo Nordisk and Eli Lilly in the GLP-1 market has spilled over into the courts in the US, with claims of misleading advertising.

News

Basketball great Shaq fronts Lilly sleep apnoea campaign

Eli Lilly has recruited basketball legend Shaquille O'Neal to promote a sleep apnoea awareness campaign and make the case for treatment with Zepbound.

Judge backs Lilly in Novo lawsuit over weight-loss drug ads

Lilly's Zepbound enhances Taltz efficacy in psoriasis study

Lilly fleshes out triple G data in diabetes and obesity

Lilly's GLP-1s race away in Q2, though Foundayo falls short

Novo sues Lilly over 'misleading' GLP-1 ad campaigning

Basketball great Shaq fronts Lilly sleep apnoea campaign

Astellas pays $285m for Audax cancer drug, and other deals

Discover a new era of healthcare panel engagement: Grounded ...

Zepbound

Editor's Picks